B Cell Tetherin: A Flow Cytometric Cell‐Specific Assay for Response to Type I Interferon Predicts Clinical Features and Flares in Systemic Lupus Erythematosus

Type I interferon (IFN) responses are broadly associated with autoimmune diseases, including systemic lupus erythematosus (SLE). Given the cardinal role of autoantibodies in SLE, this study was undertaken to investigate whether the findings of a B cell–specific IFN assay correlate with SLE activity.

[1]  E. Jones,et al.  T cell immunomodulation by clinically used allogeneic human cancellous bone fragments: a potential novel immunotherapy tool , 2018, Scientific Reports.

[2]  P. Emery,et al.  A novel two-score system for interferon status segregates autoimmune diseases and correlates with clinical features , 2018, Scientific Reports.

[3]  B. Diamond,et al.  Plasma Cell Differentiation Pathways in Systemic Lupus Erythematosus , 2018, Front. Immunol..

[4]  P. Emery,et al.  Type I interferon–mediated autoimmune diseases: pathogenesis, diagnosis and targeted therapy , 2017, Rheumatology.

[5]  P. Emery,et al.  Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus , 2017, Annals of the rheumatic diseases.

[6]  G. Burmester,et al.  High maternal expression of SIGLEC1 on monocytes as a surrogate marker of a type I interferon signature is a risk factor for the development of autoimmune congenital heart block , 2017, Annals of the rheumatic diseases.

[7]  F. Rieux-Laucat,et al.  Detection of interferon alpha protein reveals differential levels and cellular sources in disease , 2017, The Journal of experimental medicine.

[8]  S. Bolland,et al.  Expanding the B Cell-Centric View of Systemic Lupus Erythematosus. , 2017, Trends in immunology.

[9]  M. Care,et al.  Network Analysis Identifies Proinflammatory Plasma Cell Polarization for Secretion of ISG15 in Human Autoimmunity , 2016, The Journal of Immunology.

[10]  R. Maciuca,et al.  A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE) , 2015, Annals of the rheumatic diseases.

[11]  J. James,et al.  Haematological manifestations of lupus , 2015, Lupus Science & Medicine.

[12]  P. Emery,et al.  Biologics in systemic lupus erythematosus: current options and future perspectives. , 2014, British journal of hospital medicine.

[13]  M. Crow.  Type I Interferon in the Pathogenesis of Lupus , 2014, The Journal of Immunology.

[14]  Virginia Pascual,et al.  Modular Transcriptional Repertoire Analyses of Adults With Systemic Lupus Erythematosus Reveal Distinct Type I and Type II Interferon Signatures , 2014, Arthritis & rheumatology.

[15]  I. Bruce,et al.  Treat-to-target in systemic lupus erythematosus: recommendations from an international task force , 2014, Annals of the rheumatic diseases.

[16]  Andreas Radbruch,et al.  Cell-Specific Type I IFN Signatures in Autoimmunity and Viral Infection: What Makes the Difference? , 2013, PloS one.

[17]  D. Isenberg,et al.  Elevated serum BAFF levels are associated with rising anti-double-stranded DNA antibody levels and disease flare following B cell depletion therapy in systemic lupus erythematosus. , 2013, Arthritis and rheumatism.

[18]  L. Davis,et al.  SLE Peripheral Blood B Cell, T Cell and Myeloid Cell Transcriptomes Display Unique Profiles and Each Subset Contributes to the Interferon Signature , 2013, PloS one.

[19]  L. Rönnblom,et al.  The interferon signature in autoimmune diseases , 2013, Current opinion in rheumatology.

[20]  M. Care,et al.  In Vitro Generation of Long-lived Human Plasma Cells , 2012, The Journal of Immunology.

[21]  Andreas Radbruch,et al.  IFNα and its response proteins, IP-10 and SIGLEC-1, are biomarkers of disease activity in systemic lupus erythematosus , 2012, Annals of the rheumatic diseases.

[22]  J. Harley,et al.  Genetic susceptibility to lupus: the biological basis of genetic risk found in B cell signaling pathways , 2012, Journal of leukocyte biology.

[23]  D. Isenberg,et al.  B-cell numbers and phenotype at clinical relapse following rituximab therapy differ in SLE patients according to anti-dsDNA antibody levels , 2012, Rheumatology.

[24]  Saskia Vosslamber,et al.  The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients , 2012, Arthritis Research & Therapy.

[25]  T. Niewold.  Interferon alpha as a primary pathogenic factor in human lupus. , 2011, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[26]  R. Tooze,et al.  In Vitro Generation of “Long-Lived” Human Plasma Cells , 2011 .

[27]  P. Emery,et al.  B cell biomarkers of rituximab responses in systemic lupus erythematosus. , 2011, Arthritis and rheumatism.

[28]  S. Greenberg,et al.  Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway , 2011, Annals of the rheumatic diseases.

[29]  Annette Lee,et al.  Risk Alleles for Systemic Lupus Erythematosus in a Large Case-Control Collection and Associations with Clinical Subphenotypes , 2011, PLoS genetics.

[30]  Y. Takasaki,et al.  Fluctuations in the gene expression of peripheral blood mononuclear cells between the active and inactive phases of systemic lupus erythematosus. , 2010, Clinical and experimental rheumatology.

[31]  B. Diamond,et al.  The role of B cells in lupus pathogenesis. , 2010, The international journal of biochemistry & cell biology.

[32]  Andreas Radbruch,et al.  HLA-DRhigh/CD27high plasmablasts indicate active disease in patients with systemic lupus erythematosus , 2009, Annals of the rheumatic diseases.

[33]  Pei Wang,et al.  The interface between biomarker discovery and clinical validation: The tar pit of the protein biomarker pipeline , 2008, Proteomics. Clinical applications.

[34]  D. Gladman,et al.  Lack of association between the interferon-α signature and longitudinal changes in disease activity in systemic lupus erythematosus , 2008, Annals of the rheumatic diseases.

[35]  D. Dorward,et al.  The B cell receptor governs the subcellular location of Toll‐like receptor 9 leading to hyper‐responses to DNA‐containing antigens , 2008, Immunity.

[36]  Thomas Häupl,et al.  Sialic acid-binding Ig-like lectin 1 expression in inflammatory and resident monocytes is a potential biomarker for monitoring disease activity and success of therapy in systemic lupus erythematosus. , 2008, Arthritis and rheumatism.

[37]  P. Bieniasz,et al.  Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu , 2008, Nature.

[38]  I. Sanz,et al.  Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. , 2007, Arthritis and rheumatism.

[39]  R. Schreiber,et al.  Bone Marrow Stromal Cell Antigen 2 Is a Specific Marker of Type I IFN-Producing Cells in the Naive Mouse, but a Promiscuous Cell Surface Antigen following IFN Stimulation1 , 2006, The Journal of Immunology.

[40]  S. Akira,et al.  RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement , 2005, The Journal of experimental medicine.

[41]  J. Petriz,et al.  Characterization of antibodies submitted to the B cell section of the 8th Human Leukocyte Differentiation Antigens Workshop by flow cytometry and immunohistochemistry. , 2005, Cellular immunology.

[42]  D A Isenberg,et al.  Development and initial validation of an updated version of the British Isles Lupus Assessment Group ’ s disease activity index for patients with systemic lupus erythematosus , 2005 .

[43]  S. Rowland-Jones,et al.  The T cell surface--how well do we know it? , 2003, Immunity.

[44]  Virginia Pascual,et al.  Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. , 2003, Immunity.

[45]  Ash A. Alizadeh,et al.  Individuality and variation in gene expression patterns in human blood , 2003, Proceedings of the National Academy of Sciences of the United States of America.